Cancer Diagnostics Market, By Test Type (Tumor Biomarkers Tests (PSA Tests, CTC Tests, AFP Tests, CA-19 Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, KRAS Mutation Tests, Others)), Imaging (Ultrasound, Mammography, MRI Scan, PE

Cancer Diagnostics Market, By Test Type (Tumor Biomarkers Tests (PSA Tests, CTC Tests, AFP Tests, CA-19 Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, KRAS Mutation Tests, Others)), Imaging (Ultrasound, Mammography, MRI Scan, PET Scan, CT Scan, SPECT & Others), Biopsy (Needle Biopsy, Endoscopic Biopsy, Bone Marrow Biopsy, Others), Liquid Biopsy Immunohistochemistry In Situ Hybridization), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancers, Prostate Cancer, Ovarian Cancer, Stomach Cancer, Liver Cancer, Others), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cancer diagnostics are procedures used for the identification of cancer with or without incision in the body. Detection and treatment of cancer at early stages are important for long-term survival. Non-invasive cancer detection method is found to be an increasing choice of interest, owing to its painless or minimal pain method of diagnostic coupled with more accurate results. Molecular based diagnostic methods are expected to increase during the forecast period due to launches of new biomarker based detection methods. Moreover, factors like increasing incidence of cancer, increasing cancer screening rate, government initiatives, and emerging technologies such as next generation sequencing are expected to drive the market during the forecast period.
Restraints of the Global Cancer Diagnostics Market
Major factors hampering the growth of the cancer diagnostics market during the forecast period constitutes of high costs, and inadequate reimbursement.
Key features of the study:
This report provides in-depth analysis of the global cancer diagnostics market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global cancer diagnostics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Siemens AG, Bio Rad Laboratories Inc., GE Healthcare, Illumina, Inc., Koninklijke Philips N.V., Toshiba Medical Systems Corporation, Agilent Technologies, Inc., Aurora Imaging Technologies, Inc., and Quest Diagnostics
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global cancer diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Cancer Diagnostics Market, By Test Type:
Tumor Biomarkers Tests
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
Global Cancer Diagnostics Market, By Cancer Type:
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
Global Cancer Diagnostics Market, By End User:
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
Global Cancer Diagnostics Market, By Geography:
North America
By Test Type
Tumor Biomarkers Tests
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
By End User
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Country:
U.S.
Canada
Europe
By Test Type
Tumor Biomarkers Tests
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
By End User
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Test Type
Tumor Biomarkers Tests
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
By End User
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Test Type
Tumor Biomarkers Tests
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
By End User
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Test Type
Tumor Biomarkers Tests
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
By End User
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Test Type
Tumor Biomarkers Tests
PSA Tests
CTC Tests
AFP Tests
CA-19 Tests
HER2 Tests
BRCA Tests
ALK Tests
CEA Tests
EGFR Mutation Tests
KRAS Mutation Tests
Others
Imaging
Ultrasound
Mammography
MRI Scan
PET Scan
CT Scan
SPECT & Others
Biopsy
Needle Biopsy
Endoscopic Biopsy
Bone Marrow Biopsy
Others
Liquid Biopsy
Immunohistochemistry
In Situ Hybridization
By Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Melanoma
Blood Cancers
Prostate Cancer
Ovarian Cancer
Stomach Cancer
Liver Cancer
Others
By End User
Hospital Associated Labs
Independent Diagnostic Laboratories
Diagnostic Imaging Centers
Cancer Research Institutes
Others
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Abbott Laboratories *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Siemens AG
Bio Rad Laboratories Inc.
GE Healthcare
Illumina, Inc.
Koninklijke Philips N.V.
Toshiba Medical Systems Corporation
Agilent Technologies, Inc.
Aurora Imaging Technologies, Inc.
Quest Diagnostics
“*” marked represents similar segmentation in other categories in the respective section.